Rifaximin Effective for Multiple Symptoms in Irritable Bowel Syndrome With Diarrhea
Researchers analyzed the efficacy of rifaximin for relieving IBS-D symptoms, specifically abdominal pain, bloating, and bowel movement urgency.
DDW 2022
Meeting Coverage
DASH Diet May Be Protective of Incident Nonalcoholic Fatty Liver Disease Risk
Researchers investigated whether adherence to specific diets were associated with changes in liver fat or incident nonalcoholic fatty liver disease.
Early ERCP Linked to Shorter Hospitalization in Acute Biliary Pancreatitis
Researchers assessed the benefit of early vs late endoscopic retrograde cholangiopancreatography in hospitalized patients with acute biliary pancreatitis.
Eosinophilic Esophagitis Severity Index Linked to Clinical Features, Treatment Response
Researchers investigated the relationship between eosinophilic esophagitis at the time of diagnosis and disease severity, and the change in disease before and after treatment.
Concomitant PPI and Advanced Therapy Linked to Worse Outcomes in IBD
A team of investigators evaluated the effects of concomitant use of PPIs and advanced therapy on health care resources in patients with IBD.
Risk for Advanced Colorectal Neoplasia in Young Adults Tied to Age, Tobacco, and More
Presenting at DDW 2022, researchers identified the risk factors associated with the development of early-onset advanced colorectal neoplasia in young adults.
Mucosa, C-Reactive Proteins Predict Ulcerative Colitis Relapse
Normalization of 2 factors can foretell the potential for recurrence in patients who were in remission, according to a report.
Oral Microbiome Therapy Sustains Clinical Cure for Recurrent C difficile
Presenting at DDW 2022, researchers evaluated data from the PRISM3 placebo-controlled trial and the PRISM-EXT open-label extension trial of CP101, an investigational microbiome therapeutic.
Fecal Hemoglobin Concentration May Predict Advanced Neoplasia, Colorectal Cancer
Researchers developed and assessed logistic prediction models for the detection of advanced neoplasia (AN) and colorectal cancer (CRC).
Liver Test Abnormalities in Patients With COVID-19 Not Associated With Cytokine Storm
Researchers evaluated liver test abnormalities in patients hospitalized with COVID-19 and assessed cytokine levels in individuals with vs without abnormal test results.
Combined Food Allergies, Eosinophilic Esophagitis May Weaken PPI Response
While food allergies may affect response to the medication, environmental allergies do not, the report says.
Postoperative Recurrence of Crohn Disease Linked to Sex and Ethnicity
A team of researchers investigated the association between postoperative recurrence of Crohn disease and a patient’s sex and race and ethnicity.
Antibiotic Use Increases Risk for Older-Onset Inflammatory Bowel Disease
Researchers evaluated the effects of antibiotic exposure, specifically cumulative use, timing of use, and the association with older-onset IBD.
Cardiovascular Disease Higher Among Lean Patients With Nonalcoholic Fatty Liver Disease
Researchers sought to determine the prevalence of cardiovascular disease, cirrhosis, metabolic diseases, and chronic kidney disease in lean vs overweight or obese NAFLD.
Esophageal Cancer and Barrett Esophagus Increasing in Middle-Aged Adults
Researchers examined the prevalence of Barrett esophagus and esophageal cancer according to young, middle-aged, and older adult age groups.
Gallstone Disease May Help Predict Pancreatic Cancer
Researchers analyzed the incidence of gallstone disease within 1 year prior to pancreatic ductal adenocarcinoma.
Tofacitinib, Vedolizumab Effective for UC Post-Anti-TNF Agent Failure
Researchers compared the effectiveness of tofacitinib and vedolizumab among patients with UC who had experienced anti-TNF failure.
Seladelpar Safe, Potentially Effective for Cirrhosis in Primary Biliary Cholangitis
A team of researchers analyzed the safety, efficacy, and tolerability of seladelpar in patients with compensated liver cirrhosis resulting from primary biliary cholangitis.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in DDW 2022
Loading... 
Loading...